FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282971035> ?p ?o ?g. }

• W4282971035 endingPage "2019" @default.
• W4282971035 startingPage "2019" @default.
• W4282971035 abstract "Abstract Introduction: GD2 is expressed on neuroblastoma, melanomas, small cell lung cancers and sarcomas. While it is expressed minimally on normal tissues, it is expressed on nerve cells and, anti-GD2 (dinutuximab) treatment can cause neuropathic pain. To increase tumor specificity, we developed a bispecific SNIPER antibody to simultaneously target two tumor antigens (GD2 and B7H3). B7H3 is overexpressed on multiple tumor types, with minimal expression on most normal cells and is absent on nerve cells. The goal of this SNIPER is to enhance tumor-specificity, while reducing toxicity, ultimately improving efficacy for cancers expressing both targets. Experimental Procedures: SNIPER specificity was tested by flow cytometry for binding to GD2 +/- B7H3 expressing cells. Using an Incucyte S3, we tested antibody internalization properties [compared to anti-B7H3 and dinutuximab monoclonal antibodies (mAbs)] and antibody dependent cellular-cytotoxicity (ADCC) capabilities. Mice bearing variants of GD2/B7H3-expressing tumors were intravenously injected with 89Zr- radiolabeled SNIPER and its longitudinal in vivo biodistribution was monitored via positron emission tomography imaging. In vivo efficacy studies of SNIPER were tested against mice bearing either melanoma or neuroblastoma tumors that express both GD2 and B7H3. Summary of Data: In vitro and in vivo tumor specificity testing confirmed that SNIPER specifically targets B7H3+/GD2+ cells, but it does not bind to GD2+/B7H3- cells (which simulate nerve cells). We observed high internalization of anti-GD2 mAbs; we did not observe antibody internalization of either the SNIPER or anti-B7H3 mAbs. SNIPER was as effective at ADCC as the dinutuximab, but we saw minimal ADCC with the anti-B7H3 mAbs. An afucosylated version of SNIPER showed significantly enhanced ADCC compared to dinutuximab. Our in vivo efficacy studies found that SNIPER was as as dinutuximab when given at the same dose. Conclusions: The Fab arms of SNIPER targeting GD2 and B7H3 each have low-to-moderate affinity. SNIPER binds with strong avidity when both arms bind to their antigens on the same cell. Stronger avidity through both arms binding results in high-tumor specificity. Because SNIPER should not bind to nerves, it may be possible to administer increased doses of SNIPER beyond the tolerable dose of dinutuximab, which could further improve efficacy. Ongoing studies include antitumor efficacy testing, nerve binding assays and assessing reduction of pain in vivo with SNIPER. Citation Format: Amy K. Erbe, Arika Feils, Zack Rosenkrans, Jessica Wiwczar, Daniel Gerhardt, Bonnie Hammer, Mildred Felder, Mark Bercher, Alina Hampton, Lizzie Frankel, Dan Spiegelman, Noah Tsarovsky, Alexander Rakhmilevich, Jacquelyn Hank, Bryan Glaser, Reinier Hernandez, Roland Green, Paul M. Sondel. Tumor-targeting and efficacy of B7H3/GD2 bispecific SNIPER antibodies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2019." @default.
• W4282971035 created "2022-06-17" @default.
• W4282971035 creator A5005537019 @default.
• W4282971035 creator A5005684133 @default.
• W4282971035 creator A5009541047 @default.
• W4282971035 creator A5011569932 @default.
• W4282971035 creator A5015448167 @default.
• W4282971035 creator A5031252498 @default.
• W4282971035 creator A5041301339 @default.
• W4282971035 creator A5042234824 @default.
• W4282971035 creator A5052942761 @default.
• W4282971035 creator A5054772874 @default.
• W4282971035 creator A5063063260 @default.
• W4282971035 creator A5066316068 @default.
• W4282971035 creator A5075107380 @default.
• W4282971035 creator A5075731307 @default.
• W4282971035 creator A5079576105 @default.
• W4282971035 creator A5080132565 @default.
• W4282971035 creator A5088534707 @default.
• W4282971035 creator A5089532829 @default.
• W4282971035 date "2022-06-15" @default.
• W4282971035 modified "2023-09-26" @default.
• W4282971035 title "Abstract 2019: Tumor-targeting and efficacy of B7H3/GD2 bispecific SNIPER antibodies" @default.
• W4282971035 doi "https://doi.org/10.1158/1538-7445.am2022-2019" @default.
• W4282971035 hasPublicationYear "2022" @default.
• W4282971035 type Work @default.
• W4282971035 citedByCount "0" @default.
• W4282971035 crossrefType "journal-article" @default.
• W4282971035 hasAuthorship W4282971035A5005537019 @default.
• W4282971035 hasAuthorship W4282971035A5005684133 @default.
• W4282971035 hasAuthorship W4282971035A5009541047 @default.
• W4282971035 hasAuthorship W4282971035A5011569932 @default.
• W4282971035 hasAuthorship W4282971035A5015448167 @default.
• W4282971035 hasAuthorship W4282971035A5031252498 @default.
• W4282971035 hasAuthorship W4282971035A5041301339 @default.
• W4282971035 hasAuthorship W4282971035A5042234824 @default.
• W4282971035 hasAuthorship W4282971035A5052942761 @default.
• W4282971035 hasAuthorship W4282971035A5054772874 @default.
• W4282971035 hasAuthorship W4282971035A5063063260 @default.
• W4282971035 hasAuthorship W4282971035A5066316068 @default.
• W4282971035 hasAuthorship W4282971035A5075107380 @default.
• W4282971035 hasAuthorship W4282971035A5075731307 @default.
• W4282971035 hasAuthorship W4282971035A5079576105 @default.
• W4282971035 hasAuthorship W4282971035A5080132565 @default.
• W4282971035 hasAuthorship W4282971035A5088534707 @default.
• W4282971035 hasAuthorship W4282971035A5089532829 @default.
• W4282971035 hasConcept C121608353 @default.
• W4282971035 hasConcept C126322002 @default.
• W4282971035 hasConcept C139770010 @default.
• W4282971035 hasConcept C142724271 @default.
• W4282971035 hasConcept C150903083 @default.
• W4282971035 hasConcept C159654299 @default.
• W4282971035 hasConcept C170493617 @default.
• W4282971035 hasConcept C203014093 @default.
• W4282971035 hasConcept C207001950 @default.
• W4282971035 hasConcept C2776715637 @default.
• W4282971035 hasConcept C2777701055 @default.
• W4282971035 hasConcept C40677261 @default.
• W4282971035 hasConcept C502942594 @default.
• W4282971035 hasConcept C542903549 @default.
• W4282971035 hasConcept C54355233 @default.
• W4282971035 hasConcept C553184892 @default.
• W4282971035 hasConcept C71924100 @default.
• W4282971035 hasConcept C81885089 @default.
• W4282971035 hasConcept C86803240 @default.
• W4282971035 hasConceptScore W4282971035C121608353 @default.
• W4282971035 hasConceptScore W4282971035C126322002 @default.
• W4282971035 hasConceptScore W4282971035C139770010 @default.
• W4282971035 hasConceptScore W4282971035C142724271 @default.
• W4282971035 hasConceptScore W4282971035C150903083 @default.
• W4282971035 hasConceptScore W4282971035C159654299 @default.
• W4282971035 hasConceptScore W4282971035C170493617 @default.
• W4282971035 hasConceptScore W4282971035C203014093 @default.
• W4282971035 hasConceptScore W4282971035C207001950 @default.
• W4282971035 hasConceptScore W4282971035C2776715637 @default.
• W4282971035 hasConceptScore W4282971035C2777701055 @default.
• W4282971035 hasConceptScore W4282971035C40677261 @default.
• W4282971035 hasConceptScore W4282971035C502942594 @default.
• W4282971035 hasConceptScore W4282971035C542903549 @default.
• W4282971035 hasConceptScore W4282971035C54355233 @default.
• W4282971035 hasConceptScore W4282971035C553184892 @default.
• W4282971035 hasConceptScore W4282971035C71924100 @default.
• W4282971035 hasConceptScore W4282971035C81885089 @default.
• W4282971035 hasConceptScore W4282971035C86803240 @default.
• W4282971035 hasIssue "12_Supplement" @default.
• W4282971035 hasLocation W42829710351 @default.
• W4282971035 hasOpenAccess W4282971035 @default.
• W4282971035 hasPrimaryLocation W42829710351 @default.
• W4282971035 hasRelatedWork W1984195133 @default.
• W4282971035 hasRelatedWork W1985837387 @default.
• W4282971035 hasRelatedWork W2051983598 @default.
• W4282971035 hasRelatedWork W2087041936 @default.
• W4282971035 hasRelatedWork W2087664800 @default.
• W4282971035 hasRelatedWork W2094481489 @default.
• W4282971035 hasRelatedWork W2339482712 @default.
• W4282971035 hasRelatedWork W3193741685 @default.
• W4282971035 hasRelatedWork W4235655372 @default.
• W4282971035 hasRelatedWork W878840714 @default.

• next